IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 587.10, up by 5.50 points or 0.95% from its previous closing of Rs. 581.60 on the BSE.

The scrip opened at Rs. 572.05 and has touched a high and low of Rs. 592.65 and Rs. 572.05 respectively. So far 1034 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022.

Last one week high and low of the scrip stood at Rs. 607.95 and Rs. 568.00 respectively. The current market cap of the company is Rs. 11432.11 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 17.87 % and 12.52 % respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per SingleDose Prefilled Syringe. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer.

Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of $71 million for twelve months ending September 2022 according to IQVIA. Alembic has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.